Randomized phase III trial of erlotinib versus docetaxel for patients with previously treated advanced non-small cell lung cancer.

Trial Profile

Randomized phase III trial of erlotinib versus docetaxel for patients with previously treated advanced non-small cell lung cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs Erlotinib (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms DELTA
  • Most Recent Events

    • 02 Jun 2015 Results of pooled analysis of PROSE, TAILOR and DELTA trial presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 19 May 2014 Results published in the Journal of Clinical Oncology.
    • 04 Jun 2013 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top